Dow Down0.25% Nasdaq Down0.26%

Pharmacyclics Inc. (PCYC)

-NasdaqGS
123.95 Up 0.89(0.72%) Aug 28, 4:00PM EDT
|After Hours : 123.30 Down 0.65 (0.52%) Aug 28, 5:40PM EDT
ProfileGet Profile for:
Pharmacyclics Inc.
999 East Arques Avenue
Sunnyvale, CA 94085
United States - Map
Phone: 408-774-0330
Fax: 408-774-0340
Website: http://www.pharmacyclics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:521

Business Summary 

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Pharmacyclics Inc.

Corporate Governance 
Pharmacyclics Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Robert W. Duggan , 70
Chairman and Chief Exec. Officer
0.000.00
Mr. Manmeet Singh Soni , 36
Chief Financial Officer and Principal Accounting Officer
544.00K0.00
Dr. Mahkam Zanganeh D.D.S., MBA, 44
Chief Operating Officer
849.00K0.00
Mr. Heow Tan , 55
Chief of Quality & Technical Operations
708.00K814.00K
Mr. Christopher Suchet , 44
VP of Information Technology
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders